GLOBUS MEDICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Globus Medical Inc (GMED) acquired Higgs Boson Health to enhance its digital capabilities with AI-driven analytics. GMED's stock is 14.2% undervalued at $83.10 vs. GF Value™ of $96.83, with a GF Score™ of 94. Insider selling totals $15.9M, while 8 gurus hold the stock. GMED's P/E ratio is 21.25x, below its 5-year median of 40.78x.
Globus Medical (GMED) acquired AI startup Higgs Boson Health to enhance its surgical intelligence. The deal aims to integrate AI-driven software for better patient outcomes. GMED reported Q2 sales growth and raised EPS guidance. No purchase price or closing conditions were disclosed.
Globus Medical has acquired Higgs Boson Health to enhance its digital healthcare solutions using AI. The deal aims to transform patient experiences and outcomes. Financial terms were not disclosed.
Over the past 7 days, alphai's AI scored 4 news stories mentioning GMED (GLOBUS MEDICAL INC). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent GMED coverage spans earnings, mergers & acquisitions and insider activity.
In the last 30 days, GMED insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2.2M). The most active reporter was ZARRILLI STEPHEN T with 1 filing.
The deal expands Globus Medical's digital ecosystem and may boost long‑term earnings.
Potential upside from AI integration and expanded software offering.
Globus Medical has acquired Higgs Boson Health to enhance its digital healthcare solutions using AI. The deal aims to transform patient experiences and outcomes. Financial terms were not disclosed.
The deal expands Globus' product ecosystem and may boost long‑term growth, but no price or closing terms were disclosed.
The insider sale may signal reduced confidence, but size is modest relative to market cap.
alphai scores every news story that mentions GMED with an AI model for sentiment and relevance, and aggregates insider trades from GLOBUS MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Globus Medical Inc (GMED) acquired Higgs Boson Health to enhance its digital capabilities with AI-driven analytics. GMED's stock is 14.2% undervalued at $83.10 vs. GF Value™ of $96.83, with a GF Score™ of 94. Insider selling totals $15.9M, while 8 gurus hold the stock. GMED's P/E ratio is 21.25x, below its 5-year median of 40.78x.
2 min readGlobus Medical (GMED) acquired AI startup Higgs Boson Health to enhance its surgical intelligence. The deal aims to integrate AI-driven software for better patient outcomes. GMED reported Q2 sales growth and raised EPS guidance. No purchase price or closing conditions were disclosed.
2 min readGlobus Medical has acquired Higgs Boson Health to enhance its digital healthcare solutions using AI. The deal aims to transform patient experiences and outcomes. Financial terms were not disclosed.
1 min readGlobus Medical (NYSE: GMED) acquired Higgs Boson Health, a digital healthcare company focused on AI-driven solutions. The acquisition aims to enhance patient and provider experiences and improve musculoskeletal surgery outcomes. No financial details were disclosed.
2 min readZARRILLI STEPHEN T sold 25,000 shares of GLOBUS MEDICAL INC (GMED) at $87.04 ($2.18M total) on 2026-08-18.
1 min readGlobus Medical (NYSE:GMED) reported Q2 2026 sales of $789.61M, up from $745.34M, but net income fell to $151.57M from $202.85M and diluted EPS dropped to $1.10 from $1.49. For H1 2026, sales rose to $1.55B from $1.34B. The company reaffirmed full-year revenue guidance of $3.18B to $3.22B amid margin pressure.
6 min readGlobus Medical (NYSE: GMED) raised its 2026 non-GAAP EPS outlook to $4.95-$5.05 from $4.70-$4.80, while reaffirming revenue guidance of $3.18B-$3.22B. Q2 revenue rose 5.9% to $789.6M; non-GAAP diluted EPS rose 55.8% to $1.34. GAAP EPS fell due to a 2025 Nevro acquisition gain and margin expanded.
4 min readGlobus Medical (NYSE: GMED) reported Q2 2026 revenue of $789.6 million, up 5.9% year over year, and GAAP EPS of $1.10. Non-GAAP EPS was a record $1.34, beating consensus, and non-GAAP net income rose to $184.3 million. The company reaffirmed 2026 revenue guidance of $3.18–$3.22B and raised non-GAAP EPS guidance to $4.95–$5.05.
4 min readGlobus Medical (GMED) reported Q2 results on an earnings call. International spine revenue rose 12% constant-currency. Trauma revenue grew 31% YoY and 18% sequentially. Enabling Technologies revenue fell 26% YoY to $26.1M, while Excelsius placements rose. Nevro revenue declined 14.3% YoY. GAAP gross margin was 66.8%. GMED raised 2026 non-GAAP EPS to $4.95-$5.05 and reaffirmed revenue guidance of $3.18-$3.22B.
6 min readGlobus Medical (NYSE:GMED) reported Q2 CY2026 revenue of $789.6 million, up 5.9% year on year and 0.9% above analysts’ estimates, according to the company. Non-GAAP EPS was $1.34, 21.9% above consensus. The company guided full-year revenue to about $3.2 billion, near estimates.
4 min read
